Neutrophil degranulation and abnormal chemotaxis after thermal injury.

J. Davis,P. Dineen,J. Gallin

DOI: https://doi.org/10.4049/jimmunol.124.3.1467

1980-03-01

Abstract:

What problem does this paper attempt to address?

Hypertension, Orthostatic Hypotension, and the Risk of Falls in a Community‐Dwelling Elderly Population: The Maintenance of Balance, Independent Living, Intellect, and Zest in the Elderly of Boston Study

Anupama Gangavati,I. Hajjar,L. Quach,Richard N. Jones,D. Kiely,Peggy Gagnon,L. Lipsitz

DOI: https://doi.org/10.1111/j.1532-5415.2011.03317.x

2011-03-01

Journal of the American Geriatrics Society

Abstract:OBJECTIVES: To investigate the relationships between uncontrolled and controlled hypertension, orthostatic hypotension (OH), and falls in participants of the Maintenance of Balance, Independent Living, Intellect, and Zest in the Elderly of Boston Study (N=722, mean age 78.1).
Therapeutic Angiogenesis of Bone Marrow Mononuclear Cells (mncs) and Peripheral Blood Mncs: Transplantation for Ischemic Hindlimb

Hongkun Zhang,Nan Zhang,Ming Li,Hua Feng,Wei Jin,Haige Zhao,Xudong Chen,Lu Tian

DOI: https://doi.org/10.1016/j.avsg.2007.07.037

IF: 1.5

2008-01-01

Annals of Vascular Surgery

Abstract:We investigated bone marrow mononuclear cells (BM-MNCs) and peripheral blood mononuclear cells (PB-MNCs) for therapeutic angiogenesis in the ischemic hindlimb. BM-MNCs were isolated and injected into ischemic skeletal muscles in mice. Laser Doppler and histological evaluation were performed after the surgical procedure. Fifteen patients suffering from critical lower limb ischemia received subcutaneous injections of recombinant human granulocyte colony-stimulating factor (G-CSF) to mobilize progenitor cells, and PB-MNCs were harvested and transplanted directly into the ischemic limb. Endothelial cells derived from BM-MNCs were plated, then induced to form three-dimensional networks by invading a Matrigel. Four weeks after implantation of BM-MNCs, laser Doppler analysis showed that the blood flow ratio was significantly increased (0.67 +/- 0.02 vs. 0.44 +/- 0.02). Alkaline phosphatase and immunohistochemical analyses showed that capillary density was significantly increased (95.25 +/- 0.07% vs. 39.6 +/- 0.04%). Two months after implantation of PB-MNCs, in both subgroups, ankle-brachial index values, walking distance, pain scale, and transcutaneous oxygen pressure (TcO2) were significantly improved (p < 0.005). A total of six of 15 limb ulcers of transplanted patients were healed after cell transplantation. BM-MNC implantation was able to induce functional angiogenesis in mice ischemic hindlimb. This clinical trial shows that G-CSF-based PB-MNC transplantation is a feasible treatment for the ischemic hindlimb.
Efficacy of Topical Recombinant Human Platelet-Derived Growth Factor for Treatment of Diabetic Lower-Extremity Ulcers: Systematic Review and Meta-Analysis

Xiaohong Zhao,Haifeng Gu,Zhu-An Xu,Qin Zhang,Xueying Lv,Xiaojun Zheng,Yunmei Yang

DOI: https://doi.org/10.1016/j.metabol.2014.06.005

2014-01-01

Abstract:Objective Recombinant human platelet-derived growth factor (rhPDGF) is used topically in the treatment of diabetic lower-extremity ulcers. There have been few meta-analyses of the efficacy of rhPDGF in this treatment context. The aim of this study was to perform an updated systematic review and meta-analysis to assess the clinical efficacy of rhPDGF in the treatment of diabetic lower-extremity ulcers. Methods We searched the MEDLINE, Cochrane Library, EMBASE and Web of Knowledge databases up to April 30, 2014. Studies were identified and selected, and data were extracted by two independent reviewers. The primary efficacy outcome was complete healing rate. Adverse events were also assessed. The studies were evaluated for quality and publication bias. Results A total of 6 randomized controlled trials including 992 patients were selected from 173 identified studies. The studies compared rhPDGF treatment in the context of standard of care (SOC) to placebo or SOC alone. In the absence of study heterogeneity, a fixed-effects model was performed, and the combined odds ratio (OR) indicated a significantly greater complete healing rate in patients treated with rhPDGF compared to placebo or SOC alone. The ORs ranged from 0.58 to 2.77, with a combined OR of 1.53 (95% CI = 1.14 to 2.04, p = 0.004). A sensitivity analysis (leave-one-out method) indicated good study reliability, and a funnel plot with Egger test showed no publication bias. Conclusion These results indicate that rhPDGF is efficacious in the treatment of diabetic lower-extremity ulcers.
Autologous Transplantation of Peripheral Blood Stem Cell in Treatment of Critical Limb Ischemia

Hong-kun Zhang,Ming Li,Hua Feng

DOI: https://doi.org/10.3785/j.issn.1008-9292.2007.04.009

2007-01-01

Abstract:OBJECTIVE:To apply autologous transplantation of peripheral blood stem cells in the treatment of critical limb ischemia.METHODS:Fifteen patients with critical lower limb ischemia were recruited in this study. After bone marrow mobilization, peripheral blood stem cells were collected using CS-3000 Plus device, and transplanted directly into the ischemic limb. In total 17 times of transplantation were performed.RESULTS:One year after implanted peripheral blood stem cells, the pain scale decreased from 5 to 0, the ankle-brachial pressure index (ABI) increased from 0.30 to 0.46, the pain-free walking distance and maximal walking distance increased from 0.15 to 0.72 km and 0.96 to 2.13 km separately, from a total of 6 of 15 limb ulcers of transplanted patients 5 were healed after cell transplantation.CONCLUSION:Autologous peripheral blood stem cell transplantation is able to induce functional angiogenesis in ischemic limb, which can significantly reduce rest pain, increase walk distance, and promote ulcer healing.
PS106. Transplantation of Purified CD34+ Cells from Peripheral Blood in Treatment of No-option Critical Limb Ischemia: A Pilot Study

Zhihui Dong,Bin Chen,Zheng Wei,Weiguo Fu,Daqiao Guo,Xin Xu,Xiangman Zhang,Zhenyu Shi,Zhimei Wang,Shanhua Zou,Junhao Jiang,Jue Yang,Ting Zhu,Yuqi Wang

DOI: https://doi.org/10.1016/j.jvs.2011.03.297

IF: 4.86

2011-01-01

Journal of Vascular Surgery

Abstract:To evaluate the safety and efficacy of transplantation of purified peripheral blood CD34+ cells in treatment of no-option critical limb ischemia (NOCLI). From May 2009 to Nov. 2010, 15 NOCLI cases were included, 11 with thromboangitis, 2 atherosclerosis obliterans, and 2 vasculitis, mean age 44±15years. G-CSF was subcutaneously injected for 5 days before apheresis. CD34+ cells were isolated with CliniMACS system, and then intramuscularly injected into calf and foot. Technical success was achieved in all cases. Major amputation was performed in 2 cases postoperatively, and the salvage rate was 87%. The mean number of transplanted cells was (7.84±4.17) ×105/kg. The follow-up was accomplished in all cases, ranging from 1-19 months (mean 8±5months). One month after transplantation, the rest pain was obviously relieved in 11 cases, and the Wong-Baker FACES pain rating scale score significantly decreased from 7±2 to 1±1, P=0.0000. At 6 months, the pain-free walking distance on treadmill measured in 8 eligible cases was significantly improved from 3.0±3.0 min to 17.9±10.6 min (P=0.001); the ankle-brachial index increased from 0.45±0.22 to 0.69±0.13 ( P=0.007); transcutaneous partial oxygen pressure rose from 29±12mmHg to 57±9mmHg (P=0.0002). Of 9 cases with the foot ulcer, it was healed in 6 patients at 4±3months and apparently shrank in 3. No serious complications were observed either perioperatively or during the follow-up. Transplantation of purified peripheral blood CD34+ cells appeared to be safe and effective in treatment of NOCLI, and mid-to-long-term results is pending further investigation.
Transplantation of Purified CD34+ Cells in the Treatment of Critical Limb Ischemia.

Zhihui Dong,Bin Chen,Weiguo Fu,Yuqi Wang,Daqiao Guo,Zheng Wei,Xin Xu,Farrell Owen Mendelsohn

DOI: https://doi.org/10.1016/j.jvs.2013.01.037

IF: 4.86

2013-01-01

Journal of Vascular Surgery

Abstract:Background: This study investigated the feasibility, safety, and efficacy of the intramuscular injection of CD34+ cells isolated from peripheral blood mononuclear cells (PB-MNCs) mobilized by granulocyte colony-stimulating factor (G-CSF) for the management of patients with critical limb ischemia (CLI) who were considered unlikely to have successful long-term revascularization with open bypass or endovascular methods. Cell therapy represents a new treatment modality for this subgroup of patients with CLI. To date, bone marrow or PB-MNCs have usually been used for transplantation. The current pilot study investigated whether the transplantation of purified CD34+ cells only would be competent in ischemia relief and limb salvage.Methods: From May 2009 to July 2011, 25 patients (mean age, 44 +/- 12 years) were enrolled, and 25 lower extremities and three upper extremities were treated. After subcutaneous administration of G-CSF for 5 days at a dose of 5 to 10 mu g/kg, apheresis and immunomagnetic separation were performed to acquire the isolated CD34+ cells, which were then intramuscularly injected into the ischemic sites. The patients were divided into three groups: low-dose, 10(5)/kg; medium-dose, 5 x 10(5)/kg; and high-dose, 10(6)/kg. The overall outcomes among all patients and the comparison among the groups were evaluated.Results: During the follow-up of 6 to 33 months, the overall outcomes showed that the Wong-Baker FACES pain rating scale score (WFPRSS) decreased from 7 +/- 2 to 3 +/- 3 (P < .001) and 1 +/- 2 (P < .001) at 1 and 2 months, respectively; at 3 and 6 months, respectively, the peak pain-free walking time increased from 4 +/- 3 to 13 +/- 7 (P < .001) and 18 +/- 6 minutes (P < .001), the ankle-brachial index increased from 0.46 +/- 0.21 to 0.60 +/- 0.17 (P = .003) and 0.67 +/- 0.15 (P = .001), and the transcutaneous partial oxygen pressure increased from 27 +/- 10 to 41 +/- 11 (P < .001) and 55 +/- 12 mm Hg (P < .001). Ulcers were healed in 10 of the 14 patients; four patients required above-knee or below-knee amputation <= 3 months. The Kaplan-Meier estimate of the rate of freedom from major amputation at 6 months was 84% (95% confidence interval, 63%-94%). The comparison among the three groups (low-dose, 5; medium-dose, 11; high-dose, 9) revealed no significant difference, except that the WFPRSS improvement at 1 month from baseline in the high-dose group (6.3 +/- 1.7) was significantly superior to that in the low-dose (3.2 +/- 3.3; P = .0487) and medium-dose (3.7 +/- 2.8; P = .0352) groups.Conclusions: Transplantation of CD34+ cells isolated from G-CSF-mobilized PB-MNCs appears to be feasible and safe, showing encouraging outcomes in the treatment of CLI patients who appear to have compromised options for long-term revascularization.
A Five-Year Study of the Efficacy of Purified CD34+ Cell Therapy for Angiitis-Induced No-Option Critical Limb Ischemia.

Yuan Fang,Zheng Wei,Bin Chen,Tianyue Pan,Shiyang Gu,Peng Liu,Daqiao Guo,Xin Xu,Junhao Jiang,Jue Yang,Zhenyu Shi,Ting Zhu,Yun Shi,Yifan Liu,Zhihui Dong,Weiguo Fu

DOI: https://doi.org/10.1002/sctm.17-0252

2018-01-01

Stem Cells Translational Medicine

Abstract:Angiitis-induced critical limb ischemia (AICLI) patients constitute a remarkable proportion of nooption critical limb ischemia (CLI) patients. Stem cell therapy has become an innovative and promising option for no-option CLI patients. As one of these promising stem cell therapies, purified CD34+ cell transplantation (PuCeT) has shown favorable short-term results. However, the long-term efficacy of PuCeT has yet to be reported. This study evaluates the long-term efficacy of PuCeT in AICLI patients. Twenty-seven AICLI patients were enrolled from May 2009 to December 2011. Granulocyte colony-stimulating factor (G-CSF) and enoxaparin sodium were administered for 5 days. On day 5, CD34+ cell isolation was performed, and cells were transplanted by intramuscular injection. The primary endpoint, major-amputation-free survival rate (MAFS), as well as secondary endpoints, such as peak pain-free walking time (PPFWT) and the Wong-Baker FACES pain rating scale score (WFPRSS), were routinely evaluated during the 5-year follow-up period. The endpoints were as follows: the MAFS was 88.89%; PPFWT increased from 3 +/- 3 to 17 +/- 6 minutes; WFPRSS decreased from 7 +/- 2 to 0.3 +/- 1.7; the ulcer healing rate was 85.71%; the recurrence rate was 11.11%; and SF-36v2 scores were significantly improved at 5 years after PuCeT. The rate of labor recovery 5 years after PuCeT was 65.38%, and no severe adverse effect was observed during the treatment. PuCeT demonstrated long-term efficacy and durability as a treatment of AICLI not only in achieving limb salvage but also in recovering the labor competence and improving the quality of life of patients.
Efficacy of Ultrasound Microbubble-HGF Complex for Treating Hepatic Fibrosis and Its Relation with Perfusion Weighted Imaging

Shou-Hong Zhang,Ying Zhang,Kun-Ming Wen,Wei Wu,Wen-Yan Li

DOI: https://doi.org/10.17582/journal.pjz/2020.52.1.363.368

2019-01-01

Pakistan Journal of Zoology

Abstract:We explored the feasibility of treating liver fibrosis with human Hepatocyte Growth Factor (HGF) carried by biotinylated ultrasound microbubbles plus biotinlated cationic nano-liposome composites (Bio-MB+Bio-CNLP) in bile duct-ligated (BDL) rats. In addition, we investigated the staging of hepatic fibrosis by using Perfusion-Weighted Imaging (PWI). We established a BDL rat model of hepatic fibrosis. HGF carrier was administered through tail-vein injections. The gene therapy efficacy was evaluated in vivo. Before and after treatment the rats were examined with MR-PWI. The perfusion parameters of PWl were compared with the fibrosis stage. The total fibrous tissue in the liver of rats treated with HGF was lower than that in control group. The time-signal intensity curve (TIC) peak of liver parenchyma of rats with hepatic fibrosis was characterized by a slow wash-in -out. A correlation was found between the perfusion parameters and the stage of fibrosis. As the stage of fibrosis increased, the wash-in and -out rates decreased progressively. The use of Bio-MB+Bio-CNLP is an effective and novel vector for gene delivery in vivo. Further, we confirm that HGF represents a valid liver anti-fibrotic molecule. PWI might be an effective method for quantifying the severity of liver fibrosis.
P2.03a-001 A Randomized Phase III Clinical Trial of Anlotinib Hydrochloride in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC)

Baohui Han,Kai Li,Yizhuo Zhao,Qiming Wang,Li Zhang,Jianhua Shi,Zhehai Wang,Jianxing He,Yuankai Shi,Yin Cheng,Weiqiang Chen,Xiuwen Wang,Yi Luo,Kejun Nan,Faguang Jin,Jian Dong,Baolan Li,Jianying Zhou,Yinlan Chen,Donglin Wang,Xin Zhou,Yan Yu,Liming Chen,Anwen Liu,Jianjin Huang,Cheng Huang,Bangwei Cao,Jun Chen,Rui Ma,Zhuang Yu,Cuimin Ding,Hongbing Wang

DOI: https://doi.org/10.1016/j.jtho.2016.11.1210

IF: 20.121

2017-01-01

Journal of Thoracic Oncology

Abstract:Anlotinib hydrochloride, a novel multi-targeted tyrosine kinase inhibitor (TKI) was found to exhibit excellent inhibitory efficiency on a variety of receptor tyrosine kinases (RTK) involved in tumor progression, especially the vascular endothelial growth factor receptor (VEGFR), fibroblast growth factor receptor (FGFR), platelet-derived growth factor receptor (PDGFR) and stem cell-factor receptor (c-Kit). This ongoing trial aimed at evaluating the efficacy and safety of anlotinib hydrochloride comparing with placebo in advanced NSCLC patients who had received at least two previous chemotherapy and EGFR/ALK targeted therapy regimens. This Phase III, randomized, double-blind, placebo-controlled study (NCT 02388919) is ongoing in 31 centers in China under the supervision of Independent Data Monitoring Committee (IDMC). Pathological stage IIIB/IV adult advanced NSCLC patients (Pts) who had failed with at least two previous chemotherapy and EGFR/ALK targeted therapy regimens were eligible. The status of EGFR and ALK genes should be clear in all enrolled pts. Pts with sensitive EGFR or ALK mutations must had received and appeared intolerance to pervious targeted therapies. Pts were randomized (2:1) to receive Anlotinib hydrochloride or placebo once daily (12 mg) from day 1 to 14 of a 21-day cycle until progression. Dose reduction to 8 or 10 mg/day could be applied when grade 3 or 4 treatment-related toxicities were observed. The minimal sample size was estimated to 450 patients. The primary endpoint is overall survival (OS) and second endpoints are progression-free survival (PFS), overall response rate (ORR), disease control rate (DCR) and quality of life (QoL). Quality of life was assessed via EORTC QLQ-C30, safety is determined using standard NCI-CTCAE v4.02, and responses are evaluated according to RECIST v1.1. This study started in February 2015, up to early July 2016, a total of 420 pts have been enrolled (93.3 % of 450 pts). Among enrolled pts, about 80 % were diagnosed as adenocarcinoma, EGFR mutation or ALK rearrangement was found in 1/3 of the pts. The overall analyzes will start after 300 OS events. Anti-angiogenesis is the main mechanism of Anlotinib hydrochloride for preventing the tumor progression. Results of randomized, placebo-controlled Phase II trial (NCT01924195) has been reported in WCLC 2015, however, advantages in PFS (4.8 vs. 1.2 months) and OS (9.3 vs. 6.3 months) were observed in Anlotinib arm from the renewed data. Based on these exciting data, we are looking forward for the results of the Phase III trial.
The peripheral blood mononuclear cells versus purified CD34 + cells transplantation in patients with angiitis-induced critical limb ischemia trial: 5-year outcomes and return to work analysis—a randomized single-blinded non-inferiority trial

Hao Liu,Tianyue Pan,Yifan Liu,Yuan Fang,Gang Fang,Xiaolang Jiang,Bin Chen,Zheng Wei,Shiyang Gu,Peng Liu,Weiguo Fu,Zhihui Dong

DOI: https://doi.org/10.1186/s13287-022-02804-4

2022-01-01

Stem Cell Research & Therapy

Abstract:Backgrounds Patients with AICLI constitute a considerable proportion of NO-CLI patients and cannot be treated with surgical or endovascular treatment. Although cell therapy has shown satisfactory results in treating AICLI, research comparing the efficacy of treatment with the 2 kinds of cell products is rare. The aim of this study was to report the 5-year outcomes of a randomized single-blinded noninferiority trial (Number: NCT 02089828) on peripheral blood mononuclear cells (PBMNCs) and purified CD34 + cells (PCCs) transplantation for treating angiitis-induced critical limb ischemia (AICLI). Methods A randomized single-blinded non-inferiority trial (Number: NCT 02089828) was performed. Fifty patients were randomized 1:1 to the PBMNCs and PCCs groups. Efficacy outcomes, safety outcomes and patients’ work conditions were analyzed. The primary efficacy outcomes included major amputation and total amputation over 60 months. Results During the 60-month follow-up, 1 patient was lost to follow-up, 1 died, and 2 underwent major amputation. The major amputation-free survival rate (MAFS) was 92.0% (95% confidence interval [CI] 82.0%-100.0%) in the PBMNCs group and 91.7% (95% CI 81.3%-100.0%) in the PCCs group ( P = 0.980). Compared with the PCCs group, the PBMNCs group had a significantly higher 5-year new lesion-free survival rate (100.0% vs. 83.3% [95% CI 69.7–99.7%], P = 0.039). All patients lost their ability to work before transplantation, and the 5-year cumulative return to work (RTW) rates were 88.0% in the PBMNCs group and 76.0% in the PCCs group ( P = 0.085). Conclusion The long-term follow-up outcomes of this trial not only demonstrated similar efficacy and safety for the 2 types of autoimplants but also showed a satisfactory cumulative RTW rate in AICLI patients who underwent cell transplantation. Trial registration : ClinicalTrials.gov, number NCT 02089828. Registered 14 March 2014, https://clinicaltrials.gov/ct2/show/record/NCT02089828 .
Safety and Efficacy of Adenovirus Carrying Hepatocyte Growth Factor Gene by Percutaneous Endocardial Injection for Treating Post-infarct Heart Failure: A Phase IIa Clinical Trial

Haoyu Meng,Bo Chen,Zhengxian Tao,Zhihui Xu,Liansheng Wang,Ju Weizhu,Yongyong Hong,Xiang Liu,Hua Wang,Lisheng Wang,Zuze Wu,Zhijian Yang

DOI: https://doi.org/10.2174/1566523218666180404162209

2018-01-01

Current Gene Therapy

Abstract:OBJECTIVE:Our previous phase I clinical trial has confirmed the safety of Adenovirus carrying Hepatocyte Growth Factor gene (Ad-HGF) by intracoronary administration for treating severe coronary artery disease. This study was performed to evaluate the safety and efficacy of Ad-HGF by percutaneous endocardial injection for treating post-infarct heart failure.METHODS:A total of 30 patients (15 in the experimental group and 15 in the control group) with postinfarct heart failure who were not indicated to revascularization and had received the optimal standardized medication therapy were included in the study. Percutaneous endocardial Ad-HGF gene transfer was injected with a catheter-based intramyocardial delivery system in the experimental group. Safety parameters were measured and compared between baseline and follow-ups in the experimental group. The Mean Difference (MD) of efficacy parameters from baseline to 6-month follow-up was measured in both groups and compared with each other.RESULTS:No one suffered from serious adverse events in the experimental group during the 6-month follow-up. The experimental group revealed significant lower left ventricular end-diastolic dimension (LVDd) (68.5 vs. 65.8 MD: -2.69±1.08, P=0.03) and higher LVEF of both echocardiograph (35.2 vs. 39.3, MD: 4.05±0.86, P=0.0005) and single photon emission computed tomography (27.7 vs. 30.6, MD: 2.9±0.8, P=0.003) in the 6-month follow-up than that in the baseline, but the control group did not (P>0.05). Compared to the control group, the experimental group showed significant improvement ranges of lower LVDd (2.6 vs. -2.69, MD: -5.3±1.4, P=0.0009) and higher echocardiographic LVEF (-2 vs. 4.05, MD: 6.1±1.6, P=0.0008) from baseline to 6-month follow-up.CONCLUSION:Percutaneous endocardial administration of Ad-HGF is safe and potentially efficient in improving LVEF and lowering LVDd of patients with post-infarct heart failure.
Abstract 2027: Enhancing Cell-based Therapies With Peptide-modified Thermoresponsive Citrate-based Biomaterials For Treatment Of Critical Limb Ischemia

Huifeng Wang,Caitlyn Dang,Nancy Rivera-Bolanos,Ophelia Tong,Xinlong Wang,Rebecca L Riter,Chongwen Duan,Xiaomin Zhang,Chad Haney,Guillermo A Ameer,Bin Jiang

DOI: https://doi.org/10.1161/atvb.44.suppl_1.2027

2024-05-01

Abstract:Introduction: Critical limb ischemia (CLI) causes severe morbidity and mortality with limited treatment options. Cell-based therapy has potential to advance treatment outcomes but faces challenges in cell survival and engraftment during delivery. We hypothesize that an antioxidant niche that promotes cell adhesion and spreading will improve cell engraftment and survival rate, with the goal of limb salvage through improved perfusion. Methods: Thermoresponsive poly(polyethylene glycol citrate-co-N-isopropylacrylamide) (PPCN) was synthesized and conjugated with laminin-derived (A5G81) or VEGF-mimic (QK) peptides. Human umbilical vein endothelial cells (HUVECs) expressing human sodium iodine symporter (hNIS) were mixed with materials and intramuscularly injected into nude mice hindlimbs and monitored with Single Photon Emission Computed Tomography with Computed Tomography (SPECT/CT) for cell survival. Next, a hindlimb ischemia model was used to assess the efficacy of cell delivery by evaluating limb perfusion, tissue loss, functional impairment and histological examination. Results: Cells delivered with PBS or PPCN demonstrated poor cell survival, with over 90% cell loss by day 7 ( Figure 1a ). In contrast, cells delivered with PPCN-A5G81 and PPCN-QK exhibited robust SPECT signal levels for up to four weeks ( Figure 1a,b ). In the hindlimb ischemia model, materials or cells alone did not demonstrate improvement in any of the parameters over the PBS control. However, cells delivered with PPCN-A5G81 and PPCN-QK showed significantly higher blood perfusion ( Figure 1c-e ), with improved tissue salvage and motor functions ( Figure 1f-i ) for both male and female mice. Conclusion: PPCN modified with A5G81 and QK promotes cell spreading, proliferation, survival, and tissue regeneration, with potential for more effective cell-based therapies for CLI.

peripheral vascular disease,hematology
A novel low-density lipoprotein/fibrinogen apheresis method for chronic limb-threatening ischemia in patients with poor options for revascularization: A multicenter, single-arm clinical trial

Shuzo Kobayashi,Masahide Furukawa,Shigeru Ichioka,Katsumi Horiuchi,Ikuro Kitano,Miki Fujii,Shinobu Ayabe,Rica Tanaka,Norihiko Ohura,Takehiko Ohura

DOI: https://doi.org/10.1111/1744-9987.13915

Abstract:Introduction: Low-density lipoprotein (LDL) apheresis is a treatment option for patients with unhealed chronic limb-threatening ischemia (CLTI) after revascularization. The newly developed AS-25 is a direct hemoperfusion-type apheresis device that differs from conventional LDL apheresis therapy and is designed to specifically adsorb both LDL-C and fibrinogen. We evaluate the efficacy and safety of AS-25. Methods: This study included 61 patients whose ulcers failed to heal after revascularization or were ineligible for revascularization. Of these, 50 were undergoing hemodialysis. The primary endpoint was the healing rate of a target lesion of interest (ulcer), using historical data as control. Results: The ulcer healing rate of 45.9% was significantly higher than the historical data. No significant safety concerns were observed. Conclusions: AS-25 was effective in healing ulcers and preventing major amputation even in CLTI refractory patients on hemodialysis, thus showing potential clinical applicability and high significance. Clinical trial registration: UMIN study ID UMIN000020336.
Therapeutic Efficacy of CD34+ Cell-Involved Mononuclear Cell Therapy for No-Option Critical Limb Ischemia: A Meta-Analysis of Randomized Controlled Clinical Trials

Tianyue Pan,Zheng Wei,Yuan Fang,Zhihui Dong,Weiguo Fu

DOI: https://doi.org/10.1177/1358863x17752556

2018-01-01

Abstract:Early-phase clinical trials in patients with critical limb ischemia (CLI) have shown positive results of mononuclear cell therapy. The current meta-analysis investigated whether cluster of differentiation (CD) 34(+) mononuclear cell therapy (CD34(+)MCT) is effective for no-option CLI. Ten randomized controlled clinical studies of CD34(+)MCT for no-option CLI with 479 patients were identified and analyzed for pooled results. Compared to control groups, the CD34(+)MCT was associated with lower total amputation (odds ratio (OR): 0.45, p=0.01; 95% confidence interval (CI): 0.24-0.85) and a higher complete ulcer healing rate (OR: 2.80, p=0.008; 95% CI: 1.31-6.02), but showed no advantage in major amputation (OR: 0.58, p=0.11; 95% CI: 0.29-1.14) and all-cause mortality (OR: 0.82, p=0.62; 95% CI: 0.36-1.83) . Studies with a high CD34(+) cell dosage showed significant results in major amputation (OR: 0.38, p=0.002; 95% CI: 0.21-0.70), total amputation (OR: 0.31, p=0.0002; 95% CI: 0.17-0.57) and complete ulcer healing (OR: 7.58, p=0.0005; 95% CI: 2.40-23.88), which were not observed in the low-dose studies. However, inclusion of placebo-controlled studies showed no improvement of the CD34(+)MCT in total amputation (OR: 0.67, p=0.42; 95% CI: 0.25-1.79), major amputation (OR: 1.31, p=0.43; 95% CI: 0.67-2.54) or complete ulcer healing (OR: 1.52, p=0.27; 95% CI: 0.72-3.21), which were extremely significant in non-placebo-controlled studies (p<0.001). In conclusion, the significant results of CD34(+)MCT might not support its therapeutic benefit due to high placebo-effect risk and considerable heterogeneity caused by distinct cell doses. More sizable double-blinded, randomized, placebo-controlled trials with higher CD34(+) cell dosage are needed in the future.
Phase I Clinical Trial on Intracoronary Administration of Ad-hHGF Treating Severe Coronary Artery Disease

Zhi-Jian Yang,You-Rong Zhang,Bo Chen,Shu-Lan Zhang,En-Zhi Jia,Lian-Sheng Wang,Tie-Bing Zhu,Chun-Jian Li,Hui Wang,Jun Huang,Ke-Jiang Cao,Wen-Zhu Ma,Bin Wu,Li-Sheng Wang,Chu-Tse Wu

DOI: https://doi.org/10.1007/s11033-008-9315-3

IF: 2.7422

2008-01-01

Molecular Biology Reports

Abstract:OBJECTIVE:Therapeutic angiogenesis is a new strategy for treatment of vascular insufficiency. Hepatocyte growth factor (HGF)-induced angiogenesis has been applied to induce the neovascularization of ischemic adult tissues in preclinical studies. This report summarizes a phase I clinical trial on the safety of adenovirus-mediated human HGF (Ad-HGF) gene transfer to treat clinically significant coronary artery disease.METHODS:The 18 patients with severe and diffused triple vessel disease determined by coronary angiography, 1-3 of the main coronary arteries not amenable to bypassing grafting and to catheter-based revascularization were assigned to 3 study groups according to the dose of Ad-HGF (from low to high), and the total dose as follows: 5 x 10(9) pfu (group A, n = 6); 1 x 10(10) pfu (group B, n = 6); 2 x 10(10) pfu (group C, n = 6). Arterial gene transfer was performed by over-the wire balloon to the distal of the accessible artery or otherwise the ostium of the target vessels by diagnostic coronary catheter. General safety parameters and cardiac-specific parameters were measured through the preoperative period and on day 7, 21, and 35 postoperatively. The safety and tolerance of Ad-HGF for patients were evaluated according to functional and cytological assessments.RESULTS:During the acute phase up to day 35 and at 11-14 months of follow-up there were no serious adverse events. A mild fever during the first 3 days was not present at day 4, and no long term or paroxysmal fever was found. There were no acute alterations in hemodynamic parameters and the electrocardiogram remained normal. No serious pericardial effusion was reported and there were no arrhythmia on Holter registrations. Moreover, the serum levels of HGF were not changed and the serum anti-adenovirus in the patients was not detected up to day 35.CONCLUSIONS:The present study demonstrates that it is feasible to safely use an adenovirus gene-transfer vector to deliver the human hepatocyte growth factor gene to individuals with clinically significant coronary artery disease by direct intracoronary injection. However, a great deal of additional work must be done before administration of Ad-HGF can be recommended for clinical practice.
Report of a phase 1 clinical trial for safety assessment of human placental mesenchymal stem cells therapy in patients with critical limb ischemia (CLI)

Zeinab Shirbaghaee,Saeed Heidari Keshel,Mehdi Rasouli,Majid Valizadeh,Seyed Saeed Hashemi Nazari,Mohammad Hassani,Masoud Soleimani

DOI: https://doi.org/10.1186/s13287-023-03390-9

2023-07-05

Abstract:Background: Critical limb ischemia (CLI) is associated with increased risk of tissue loss, leading to significant morbidity and mortality. Therapeutic angiogenesis using cell-based treatments, notably mesenchymal stem cells (MSCs), is essential for enhancing blood flow to ischemic areas in subjects suffering from CLI. The objective of this study was to evaluate the feasibility of using placenta-derived mesenchymal stem cells (P-MSCs) in patients with CLI. Methods: This phase I dose-escalation study investigated P-MSCs in nine CLI patients who were enrolled into each of the two dosage groups (20 × 106 and 60 × 106 cells), delivered intramuscularly twice, two months apart. The incidence of treatment-related adverse events was the primary endpoint. The decrease in inflammatory cytokines, improvement in the ankle-brachial pressure index (ABI), maximum walking distance, vascular collateralization, alleviation of rest pain, healing of ulceration, and avoidance of major amputation in the target leg were the efficacy outcomes. Results: All dosages of P-MSCs, including the highest tested dose of 60 × 106 cells, were well tolerated. During the 6-month follow-up period, there was a statistically significant decrease in IL-1 and IFN-γ serum levels following P-MSC treatment. The blood lymphocyte profile of participants with CLI did not significantly differ, suggesting that the injection of allogeneic cells did not cause T-cell proliferation in vivo. We found clinically substantial improvement in rest pain, ulcer healing, and maximum walking distance after P-MSC implantation. In patients with CLI, we performed minor amputations rather than major amputations. Angiography was unable to demonstrate new small vessels formation significantly. Conclusion: The observations from this phase I clinical study indicate that intramuscular administration of P-MSCs is considered safe and well tolerated and may dramatically improve physical performance and minimize inflammatory conditions in patients with CLI. Trial registration: IRCT, IRCT20210221050446N1. Registered May 09, 2021.
A Randomized, Double-blind, Placebo-controlled Trial of DL-3-n-butylphthalide in Amyotrophic Lateral Sclerosis Patients

Mingsheng Liu,Xiaoli Yao,Xusheng Huang,Huifang Shang,Dongsheng Fan,Jia He,Liying Cui

DOI: https://doi.org/10.21203/rs.3.rs-1142455/v1

2021-01-01

Abstract:Background: To determine the efficacy and safety of DL-3-n-butylphthalide (NBP) for the treatment of amyotrophic lateral sclerosis (ALS).Methods: A randomized, double-blind, placebo-controlled trial was performed at 19 ALS clinical centers of the Chinese ALS Association. Patients with definite or probable ALS were randomly treated with NBP or placebo for 12 months. The Revised Amyotrophic Lateral Sclerosis Functional Rating Scale (ALSFRS-R) score was the primary endpoint and was evaluated every 3 months. Secondary endpoints included survival and tracheotomy incidence, total Medical Research Council (MRC) score, percentage of predicted forced vital capacity (FVC), and clinical global impression scale score assessed using the visual analog scale. Results: Between November 23, 2015 and November 22, 2017, 312 ALS patients were enrolled and randomly allocated to either the NBP group (156 patients) or placebo group (156 patients). Ninety-three patients in the NBP group and 92 patients in the placebo group were included in the primary end point analysis. There was no significant difference in the ALSFRS-R score, total MRC score, or clinical global impression between the two groups after treatment. The NBP group exhibited a mild trend of less decrease in the percentage of predicted FVC between baseline and the 12-month visit than the placebo group (least-squares mean change from baseline ± standard error: -7.34±4.28, 95％CI(-15.24,0.56), p=0.0335). Adverse events were reported in 56.5% of patients in the placebo group and 68.8% of patients in the NBP group (χ2=2.99, P=0.0838). No serious adverse event related to treatment occurred.Conclusion: we found no evidence that NBP improved the ALSFRS-R score in patients with ALS. The results suggest a mild trend in the percentage of predicted FVC decreased slowly in the NBP treatment group than in the placebo group.Trial registration: A Multi-center, Randomized, Double Blinding, Placebo-Controlled Clinical Trial of Dl-3-Butylphthalide in the Treatment of Amyotrophic Lateral Sclerosis, ChiCTR-IPR-15007365, Registered 1 November 2015, http://www.chictr.org.cn/showproj.aspx?proj=12354
Long-Term Outcomes of Peripheral Blood Mononuclear Cells in the Treatment of Angiitis-Induced No-Option Critical Limb-Threatening Ischemia

Xiaolang Jiang,Hao Liu,Tianyue Pan,Shiyang Gu,Yuan Fang,Zheng Wei,Gang Fang,Bin Chen,Junhao Jiang,Yun Shi,Peng Liu,Weiguo Fu,Zhihui Dong

DOI: https://doi.org/10.3389/fcvm.2021.769472

IF: 3.6

2021-12-06

Frontiers in Cardiovascular Medicine

Abstract:Background: Peripheral blood mononuclear cells (PBMNCs) showed encouraging short outcomes in the treatment of angiitis-induced no-option critical limb-threatening ischemia (AICLTI) in the pilot study. This study aimed to demonstrate the long-term outcomes of this treatment. Methods: From May 2014 to December 2018, patients diagnosed with AICLTI and treated by autotransplantation of PBMNCs in our center were enrolled and analyzed. The primary endpoint was major amputation-free survival (MAFS), the secondary endpoints included peak pain-free walking time (PPFWT), Wong-Baker FACES pain rating scale score (WFPRSS), labor recovery, ankle-brachial index (ABI), transcutaneous partial oxygen pressure (TcpO2), and SF-36v2 scores. Results: A total of 58 patients were enrolled. During a minimal follow-up of 36 months, the MAFS was 93.1% and the labor competence restored rate was 62.1%. The WFPRSS was decreased from 8.7 ± 1.6 to 1.6 ± 3.2, and PPFWT was significantly improved from 2.9 ± 4.2 min to 16.6 ± 6.9 min. The quality of life was also significantly improved at each follow-up point. Perfusion evaluating parameters, such as ABI and TcPO2, were also significantly improved. No critical adverse event was observed during the treatment and follow-up period. Conclusions: The treatment of AICLTI by autotransplantation of PBMNCs demonstrated encouraging long-term results. It could not only restore labor competence, improve the quality of life, but also significantly reduce the major amputation rate.

cardiac & cardiovascular systems
Purified CD34+ Cells Versus Peripheral Blood Mononuclear Cells in the Treatment of Angiitis-Induced No-Option Critical Limb Ischaemia: 12-Month Results of a Prospective Randomised Single-Blinded Non-Inferiority Trial

Zhihui Dong,Tianyue Pan,Yuan Fang,Zheng Wei,Shiyang Gu,Gang Fang,Yifan Liu,Yang Luo,Hao Liu,Tiejun Zhang,Meiyu Hu,Daqiao Guo,Xin Xu,Bin Chen,Junhao Jiang,Jue Yang,Zhenyu Shi,Ting Zhu,Yun Shi,Peng Liu,Weiguo Fu

DOI: https://doi.org/10.1016/j.ebiom.2018.08.038

IF: 11.205

2018-01-01

EBioMedicine

Abstract:Background: Peripheral blood mononuclear cells (PBMNCs) and purified CD34(+) cells (PCCs) are increasingly being used at treating no-option critical limb ischaemia (NO-CU). We aimed to compare the efficacies and uncover the advantages associated with each treatment approach. Methods: A randomised single-blinded non-inferiority trial (Number: NCT02089828) was performed. NO-CLI patients were 1:1 randomised to the PBMNCs and PCCs groups, and compared in relation to safety and efficacy outcomes. The primary efficacy outcomes included major amputation and total amputation over 12 months. The major amputation-free survival (MAFS) and total amputation-free survival (TAFS) rates were calculated. Findings: Fifty patients (25 per group, 47 with thromboangiitis obliterans and 3 with other angiitis) were enrolled, with a median follow-up period of 24.5 months (interquartile range: 17-34 months). One patient in the PCCs group was lost at 2 months and one major amputation occurred in the PBMNCs group at 3 months post-transplantation. The total amputation rates at 6 months post-transplantation were 28.0% in the PCCs group and 16.0% in the PBMNCs group (p = 0.343), and remained unchanged at 12 months. The groups did not differ regarding the MAFS and TAB (Breslow-Wilcoxon test: p = 03014 and p = 0.3414). The PCCs group had a significantly higher probability of rest pain relief than the PBMNCs group (Breslow-Wilcoxon test: p = 0.0454). Interpretation: PCCs was not inferior to PBMNCs at limb salvage in the treatment of angiitis-induced NO-CU and appeared to induce earlier ischaemia relief. Each cell type had specific advantages. These outcomes require verification from longer-term trials involving larger numbers of patients. (C) 2018 The Authors. Published by Elsevier B.V.
Gene therapy for diabetic foot ulcers: Interim analysis of a randomised, placebo‐controlled phase 3 study of VM202 (ENGENSIS), a plasmid DNA expressing two isoforms of human hepatocyte growth factor

Emerson Perin,Lacey Loveland,Joseph Caporusso,Cyaandi Dove,Travis Motley,Felix Sigal,Mher Vartivarian,Francisco Oliva,David G Armstrong,the VMNHU‐003 study group

DOI: https://doi.org/10.1111/iwj.14226

2023-05-27

International Wound Journal

Abstract:To evaluate the status of a 7‐month phase 3 study conducted to test the effect of intramuscular injections of VM202 (ENGENSIS), a plasmid DNA encoding human hepatocyte growth factor, into the calf muscles of chronic nonhealing diabetic foot ulcers with concomitant peripheral artery disease. The phase 3 study, originally aimed to recruit 300 subjects, was discontinued because of slow patient recruitment. An unprespecified interim analysis was performed for the 44 subjects enrolled to assess the status and determine the future direction. Statistical analyses were carried out for the Intent‐to‐Treat (ITT) population and separately for subjects with neuroischemic ulcers, using a t‐test and Fisher's exact test. A logistic regression analysis was also conducted. VM202 was safe and potentially should have benefits. In the ITT population (N = 44), there was a positive trend toward closure in the VM202 group from 3 to 6 months but with no statistical significance. Levels of ulcer volume or area were found to be highly skewed between the placebo and VM202 groups. Forty subjects, excluding four outliers in both arms, showed significant wound‐closing effects at month 6 (P = .0457). In 23 patients with neuroischemic ulcers, the percentage of subjects reaching complete ulcer closure was significantly higher in the VM202 group at months 3, 4, and 5 (P = .0391, .0391, and .0361). When two outliers were excluded, a significant difference was evident in months 3, 4, 5, and 6 (P = .03 for all points). A potentially clinically meaningful 0.15 increase in Ankle‐Brachial Index was observed in the VM202 group at day 210 in the ITT population (P = .0776). Intramuscular injections of VM202 plasmid DNA to calf muscle may have promise in the treatment of chronic neuroischemic diabetic foot ulcers (DFUs). Given the safety profile and potential healing effects, continuing a larger DFU study is warranted with modifications of the current protocol and expansion of enrolling sites.

dermatology,surgery

Neutrophil degranulation and abnormal chemotaxis after thermal injury.

Hypertension, Orthostatic Hypotension, and the Risk of Falls in a Community‐Dwelling Elderly Population: The Maintenance of Balance, Independent Living, Intellect, and Zest in the Elderly of Boston Study

Therapeutic Angiogenesis of Bone Marrow Mononuclear Cells (mncs) and Peripheral Blood Mncs: Transplantation for Ischemic Hindlimb

Efficacy of Topical Recombinant Human Platelet-Derived Growth Factor for Treatment of Diabetic Lower-Extremity Ulcers: Systematic Review and Meta-Analysis

Autologous Transplantation of Peripheral Blood Stem Cell in Treatment of Critical Limb Ischemia

PS106. Transplantation of Purified CD34+ Cells from Peripheral Blood in Treatment of No-option Critical Limb Ischemia: A Pilot Study

Transplantation of Purified CD34+ Cells in the Treatment of Critical Limb Ischemia.

A Five-Year Study of the Efficacy of Purified CD34+ Cell Therapy for Angiitis-Induced No-Option Critical Limb Ischemia.

Efficacy of Ultrasound Microbubble-HGF Complex for Treating Hepatic Fibrosis and Its Relation with Perfusion Weighted Imaging

P2.03a-001 A Randomized Phase III Clinical Trial of Anlotinib Hydrochloride in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC)

The peripheral blood mononuclear cells versus purified CD34 + cells transplantation in patients with angiitis-induced critical limb ischemia trial: 5-year outcomes and return to work analysis—a randomized single-blinded non-inferiority trial

Safety and Efficacy of Adenovirus Carrying Hepatocyte Growth Factor Gene by Percutaneous Endocardial Injection for Treating Post-infarct Heart Failure: A Phase IIa Clinical Trial

Abstract 2027: Enhancing Cell-based Therapies With Peptide-modified Thermoresponsive Citrate-based Biomaterials For Treatment Of Critical Limb Ischemia

A novel low-density lipoprotein/fibrinogen apheresis method for chronic limb-threatening ischemia in patients with poor options for revascularization: A multicenter, single-arm clinical trial

Therapeutic Efficacy of CD34+ Cell-Involved Mononuclear Cell Therapy for No-Option Critical Limb Ischemia: A Meta-Analysis of Randomized Controlled Clinical Trials

Phase I Clinical Trial on Intracoronary Administration of Ad-hHGF Treating Severe Coronary Artery Disease

Report of a phase 1 clinical trial for safety assessment of human placental mesenchymal stem cells therapy in patients with critical limb ischemia (CLI)

A Randomized, Double-blind, Placebo-controlled Trial of DL-3-n-butylphthalide in Amyotrophic Lateral Sclerosis Patients

Long-Term Outcomes of Peripheral Blood Mononuclear Cells in the Treatment of Angiitis-Induced No-Option Critical Limb-Threatening Ischemia

Purified CD34+ Cells Versus Peripheral Blood Mononuclear Cells in the Treatment of Angiitis-Induced No-Option Critical Limb Ischaemia: 12-Month Results of a Prospective Randomised Single-Blinded Non-Inferiority Trial

Gene therapy for diabetic foot ulcers: Interim analysis of a randomised, placebo‐controlled phase 3 study of VM202 (ENGENSIS), a plasmid DNA expressing two isoforms of human hepatocyte growth factor